Eric C. Lee, M.D.
Specialist
1238 E Arrow Hwy
Upland, CA 91786
Who else practices at this address →
San Bernardino County includes primary care (5% of residents) and mental health (26% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Js Weill Medical College, Cornell University (1997)
- Years since graduation
- 29
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 562
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1997Medical school: Js Weill Medical College, Cornell University
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Specialist primary
CA license A67823
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- San Antonio Regional Hospital Upland, CA
- Pomona Valley Hospital Medical Center Pomona, CA
- Casa Colina Hospital Pomona, CA
Medical groups
- Inland Rheumatology and Osteoporosis Medical Group Inc (4 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 562
- Services billed
- 397,853
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 168,000 | 47 |
| Injection, tocilizumab, 1 mg | 62,992 | 13 |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 30,350 | 49 |
| Injection, golimumab, 1 mg, for intravenous use | 26,202 | 28 |
| Injection, infliximab, excludes biosimilar, 10 mg | 14,244 | 60 |
| Injection, denosumab, 1 mg | 11,821 | 121 |
| Injection, romosozumab-aqqg, 1 mg | 11,550 | 13 |
| Measurement of antibody for assessment of autoimmune disorder, any method | 2,552 | 284 |
| Gammaglobulin (immune system protein) measurement | 2,361 | 281 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,728 | 61 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Methotrexate (methotrexate sodium) Other prescribers in Upland, CA | 405 |
| Prednisone Other prescribers in Upland, CA | 267 |
| Alendronate Sodium Other prescribers in Upland, CA | 169 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Upland, CA | 140 |
| Leflunomide Other prescribers in Upland, CA | 93 |
| Hydroxychloroquine Sulfate Other prescribers in Upland, CA | 91 |
| Meloxicam Other prescribers in Upland, CA | 83 |
| Tramadol Hcl Other prescribers in Upland, CA | 74 |
| Gabapentin Other prescribers in Upland, CA | 71 |
| Acetaminophen-Codeine (acetaminophen with codeine) Other prescribers in Upland, CA | 63 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 9 companies reported 57 payments worth $1,196 in total to this clinician.
| Amgen Inc. | $295 |
|---|---|
| Pfizer Inc. | $218 |
| Novartis Pharmaceuticals Corporation | $203 |
| GlaxoSmithKline, LLC. | $149 |
| AbbVie Inc. | $140 |
| Janssen Biotech, Inc. | $101 |
| Organon LLC | $41.21 |
| UCB, Inc. | $26.30 |
| Food and Beverage | $1,196 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 17 industry-funded studies in 2025, from 10 companies. The companies reported $460,888 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity
Amgen Inc. - ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)?
Janssen Research & Development, LLC - A Phase 2a Multicenter, Randomized, Double Blind, Parallel, Proof of concept Study Evaluating the Efficacy and Safety of Nipocalimab and Certolizumab Combination Therapy in Participants with Active Rheumatoid Arthriti…
Janssen Research & Development, LLC - A Multicenter Randomized Double-blind Placebo-controlled Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus
AstraZeneca UK Limited - M15-572 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Dr…
AbbVie Inc. - A Phase III, Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (VAYHIT1)
Novartis Pharmaceuticals Corporation - A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgrens Syndrome With Moderate-to-Severe Systemic Disease Activity
Amgen Inc. - A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
UCB SA · Completed · NCT04436640 - A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficacy and safety of secukinumab compared to placebo in adult patients with active rotator cuff tendin…
Novartis Pharmaceuticals Corporation - A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
AbbVie Inc. · Recruiting · NCT06972446
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.